The Dosage and Administration section has been revised to state that Mavyret is recommended for 12 weeks in liver or kidney transplant recipients. The Food and Drug Administration (FDA) has approved ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mavyret demonstrated 97% sustained virologic response in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AbbVie’s hepatitis C blockbuster Mavyret could soon also be an eight-week treatment for patients with compensated cirrhosis, thanks to positive new phase 3b data. That would give it more firepower as ...

AbbVie has received the Food and Drug Administration’s nod for a new indication for Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ...

Please provide your email address to receive an email when new articles are posted on . The approval allows for immediate treatment following diagnosis. Patients treated in a phase 3 study experienced ...

Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes ...

AbbVie is pushing its time-to-cure advantage in new ads for hepatitis C treatment Mavyret. Its TV ads emphasize a cure “in only 8 weeks,” with actors who portray patients repeating the phrase as they ...